|Posted by George Freund on March 15, 2020 at 10:00 AM|
German officials are trying to stop the US from enticing German company CureVac to move its research to the US, insisting no country should have a monopoly on any future vaccine. President Donald Trump had offered funds to lure the company CureVac to the US to reportedly get the vaccine exclusively for Americans
Donald Trump has offered funds to lure German company CureVac to the US
Germany government has made counter-offers to make the company stay
Germany is trying to stop the US from enticing CureVac to move its research to the US, insisting no country should have a monopoly on any future vaccine
Trump is reportedly trying to secure the scientists' work exclusively for the US
CureVac said last week they are working with a multitude of coronavirus vaccine candidates and was now selecting the two best to go into clinical trials
CureVac CEO Daniel Menichella met Trump and the White House Coronavirus Task Force to discuss a vaccine on March 2
Curevac is a private company founded in 2008 based in Tuebingen with other sites in Frankfurt and Boston
Company aims to have an experimental vaccine ready by June or July then will seek the go-ahead from regulators for testing on humans
Coronavirus symptoms: what are they and should you see a doctor?
By REUTERS and MARLENE LENTHANG FOR DAILYMAIL.COM
PUBLISHED: 09:01 EDT, 15 March 2020 | UPDATED: 09:32 EDT, 15 March 2020
German officials are trying to stop the Trump administration from luring German biopharmeceutical company CureVac to the US to get its experimental coronavirus vaccines exclusively for Americans.
President Donald Trump has offered funds to lure the company CureVac to the US. The German government has made counter-offers to make the company stay, according to a report in German newspaper Welt am Sonntag.
An unidentified German government source told the paper Trump is trying to secure the scientists' work exclusively, and would do anything to get a vaccine for the United States - 'but only for the United States.'
CureVac said last week they are working on with a multitude of coronavirus vaccine candidates and are selecting the two best to go into clinical trials.
The company's CEO met with President Donald Trump and the White House Coronavirus Task Force to discuss a vaccine earlier this month.
German politicians are now insisting that no country should have a monopoly on any future vaccine.
KNOW YOUR ENEMY!!! BETTER THAT SMALLPOX LADEN BLANKETS
CureVac is a biopharmaceutical company headquartered in Tübingen, Germany, that develops therapies based on messenger RNA (mRNA). The company's focus is on developing vaccines for infectious diseases and drugs to treat for cancer and rare diseases. Founded in 2000, CureVac had approximately 240 employees in November 2015 and 375 in May 2018.
CureVac has entered into various collaborations with organizations, including agreements with Boehringer Ingelheim, Sanofi Pasteur, Johnson & Johnson, Genmab, the Bill & Melinda Gates Foundation, Eli Lilly and Company, Coalition for Epidemic Preparedness Innovations, and the International AIDS Vaccine Initiative.
In October 2013 Curevac launched a collaboration with Janssen Pharmaceuticals Inc., a Johnson & Johnson company, for the development of novel flu vaccines. Also in 2013, CureVac announced the fourth in a series of partnerships with the Cancer Research Institute and Ludwig Cancer Research to enable clinical testing of novel cancer immunotherapy treatment options.
On March 2014, CureVac won a €2 million prize awarded by the European Commission to stimulate new vaccine technologies that might help the developing world, because the company's research could lead to a new generation of vaccines that don't need refrigeration. Later, in July 2014, CureVac signed an exclusive license agreement with Sanofi Pasteur to develop and commercialize an mRNA-based prophylactic vaccine. By September 2014, the company licensed the global rights for its Phase I candidate – CV9202 – to Boehringer Ingelheim. Boehringer was to conduct trials using the mRNA vaccine in combination with afatinib in advanced and/or metastatic epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer (NSCLC) as well as inoperable stage III NSCLC.
In March 2015, CureVac's investor, the Bill & Melinda Gates Foundation, agreed to provide separate funding for several projects to develop prophylactic vaccines based on CureVac's proprietary mRNA platform. By September 2015, CureVac entered into a collaboration with the International AIDS Vaccine Initiative (IAVI) to accelerate the development of AIDS vaccines, utilizing immunogens developed by IAVI and partners, delivered via CureVac's mRNA technology. That same month, CureVac announced it would open a United States hub in Boston, Massachusetts.
In accordance with its deal with Lilly, the company began construction on a production facility in 2016. By 2017, CureVac had received approximately US$359 million (€305 million) in equity investments and was valued at US$1.65 billion (€1.40 billion).